Tuesday November 12, 2019
Home Lead Story China Launche...

China Launches Rocket from Mobile Platform at Yellow Sea for First Time

China is the third country after the U.S. and Russia to master sea launch technology

0
//
mobile rocket, yellow sea
A Long March 11 carrier rocket takes off from a mobile launch platform in the Yellow Sea off Shandong province, China, June 5, 2019. VOA

China on Wednesday launched a rocket from a mobile platform at sea for the first time, sending a five commercial satellites and two others containing experimental technology into space.

The Long March 11 rocket blasted off from a launch pad aboard a commercial ship in the Yellow Sea off the coast of Shandong province, marking the 306th launch of a rocket in the Long March series, but the first one at sea. China is the third country after the U.S. and Russia to master sea launch technology.

Sea launches offer advantages such as the ability to position closer to the equator, requiring less fuel to reach orbit and thereby lowering overall launch costs.

mobile platform, rocket, yellow sea
China is the third country after the U.S. and Russia to master sea launch technology. VOA

It also reduces the possibility of damage on the ground from falling rocket debris.
The official Xinhua News Agency cited experts as saying seaborne launch technology will meet the growing demand for launches of low inclination satellites.

ALSO READ: Japan to Provide Low-Cost Rocket Services to Compete with US Rivals

China’s space program has developed rapidly, especially since it conducted its first crewed mission in 2003, becoming just the third country following Russia and the U.S. to put humans into space using its own technology.

It has put two space stations into orbit and plans to launch a Mars rover in the mid-2020s. Its space program suffered a rare setback last year with the failed launch of a Long March 5 rocket. (VOA)

Next Story

China Okays Sale of First Home-Grown Drug for Treatment of Mild to Moderate Alzheimer’s Disease

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020

0
China, Home, Drug
Oligomannate will provide a new treatment option to fight Alzheimer's disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday. Pixabay

China has approved the first home-grown drug for the treatment of “mild to moderate Alzheimer’s disease (AD) and improving cognitive function”, according to its developers.

The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences.

Oligomannate will provide a new treatment option to fight Alzheimer’s disease for patients and is expected to be available in China by the end of 2019, Green Valley Pharmaceutical said on Saturday.

A multi-centre global phase 3 clinical trial with sites in the US, Europe and Asia is planned to be initiated in early 2020 to support global regulatory filing of Oligomannate.

China, Home, Drug
The new drug, Oligomannate (GV-971), is the first to be approved for Alzheimer’s disease globally since 2003, said Green Valley Pharmaceutical Co., which developed the drug along with Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences. Pixabay

An effective treatment for Alzheimer’s that affects about 48 million people in the world could easily become a big hit globally.

China’s National Medical Products Administration granted Oligomannate fast-track review in November 2018.

Over 800 patients with the diagnosis of mild to moderate Alzhemer’s disease completed the Phase 3 clinical trial conducted in 34 tier-1 hospitals across China.

Results of the 36-week-long study showed that Oligomannate can improve cognitive function in mild-to-moderate Alzheimer’s disease patients as early as week 4 and the benefit was sustained at each follow-up assessment visit.

Also Read- Bengal Focuses on Alternatives after Banning Stubble Burning

Alzheimer’s disease is a progressive brain disorder that impairs memory, affecting the ability of patients to carry out simple tasks. (IANS)